Lyophilized formulations of cd73 compounds

An aqueous formulation comprising a compound of Formula (I)

• or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein,
• W is selected from the group consisting of CRe and N;
• X is selected from the group consisting of O, CH2, and S;
• each of Y and Z is independently selected from the group consisting of CH and N:
• Rg is H or the two Rg groups are combined to form an acetonide;
• Ra is selected from the group consisting of NH2, NHR1, and NR1R2;
• Rc is selected from the group consisting of H, halogen, haloalkyl, NH2, NHR3, NR3R4, R3, OH, OR3,SR3, SO2R3, —X1—NH2, —X1—NHR3, —X1—NR3R4, —X1—OH, —X1—OR3, —X1—SR3, and —X1—SO2R3;
• Re is selected from the group consisting of H, halogen, and optionally substituted C1-C6 alkyl;
• each X1 is C1-C4 alkylene;
• and
• each R1, R2, R3, and R4 is independently selected from the group consisting of optionally substituted C1-C10 alkyl, optionally substituted C3-C7 cycloalkyl, optionally substituted C3-C7 cycloalkyl C1-C4 alkyl, optionally substituted 4-7 membered heterocycloalkyl, optionally substituted 4-7 membered heterocycloalkyl C1-C4 alkyl, optionally substituted aryl, optionally substituted aryl C1-C4 alkyl, optionally substituted heteroaryl, and optionally substituted heteroaryl C1-C4 alkyl, or when R1 and R2 or R3 and R4 are attached to the same nitrogen, they combine to form a 4- to 7-membered heterocyclic ring;
• one or more amino acids and optionally a pH-adjusting agent in an amount sufficient to adjust the pH of the solution to between about 6 and about 8.

An aqueous formulation comprising

• about 15% to about 20% by weight of a compound of Formula (Ia)
• or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
• about 20% to about 35% by weight of one or more amino acids;
• about 2% to about 5% by weight of phosphoric acid;
• and
• about 40% to about 60% by weight of a bulking agent;
• wherein percentage by weight (% by weight) is based on the total weight of a lyophilized formulation that is dissolved in water to form the aqueous formulation.

An aqueous formulation comprising

• about 107.5 mg of a compound of Formula (Ia)
• or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
• about 145.34 mg of arginine;
• about 21.8 mg of phosphoric acid;
• and
• about 344 mg of mannitol.

An aqueous formulation comprising

• about 107.5 mg of a compound of Formula (Ia)
• or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
• about 145.34 mg of arginine;
• about 21.8 mg of phosphoric acid;
• and
• about 200 mg of glycine.